<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01273246</url>
  </required_header>
  <id_info>
    <org_study_id>EV71-1001-Ib</org_study_id>
    <nct_id>NCT01273246</nct_id>
  </id_info>
  <brief_title>Safety of an Inactivated Enterovirus Type 71 Vaccines in Healthy Children</brief_title>
  <official_title>A Blind, Randomized and Placebo-controlled Clinical Trial With Inactivated Enterovirus Type 71 Vaccines in Healthy Children.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sinovac Biotech Co., Ltd</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sinovac Biotech Co., Ltd</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A Phase I clinical trialto evaluate the safety of an Inactivated Enterovirus Type 71 Vaccine
      in healthy children (3-11y) and infants (6-35m).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      36 eligible children aged from 3 to 11 years and 96 eligible infants aged from 6 to 35 months
      will be enrolled in the study, they will be randomized to receive different dosage of vaccine
      candidate or placebo to evaluate the safety of this vaccine
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2011</start_date>
  <completion_date type="Actual">July 2011</completion_date>
  <primary_completion_date type="Actual">June 2011</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Participant, Care Provider)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To evaluate the safety of the inactivated Enterovirus Type 71 Vaccine</measure>
    <time_frame>6 months</time_frame>
    <description>All adverse events were records. Blood cell and biochemistry were performed.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>To evaluate the immunogenicity of the inactivated Enterovirus Type 71 Vaccine</measure>
    <time_frame>6 months</time_frame>
    <description>virus neutralization assays were performed.</description>
  </secondary_outcome>
  <number_of_arms>10</number_of_arms>
  <enrollment type="Actual">132</enrollment>
  <condition>Hand-foot-mouth Disease</condition>
  <condition>Infection; Viral, Enterovirus</condition>
  <arm_group>
    <arm_group_label>Children Group 1: 200U EV71 vaccine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>12 children received 3 doses of 200U EV71 vaccine 28 days apart</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Children Group 1: Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>6 children received 3 doses of placebo 28 days apart</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Children Group 2: 400U EV71 vaccine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>12 children received 3 doses of 400U EV71 vaccine 28 days apart</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Children Group 2: Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>6 children received 3 doses of placebo 28 days apart</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Infants Group 1: 100U EV71 vaccine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>24 infants received 3 doses of 100U EV71 vaccine 28 days apart</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Infants Group 1: Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>8 infants received 3 doses of placebo 28 days apart</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Infants Group 2: 200U EV71 vaccine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>24 infants received 3 doses of 200U EV71 vaccine 28 days apart</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Infants Group 2: Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>8 infants received 3 doses of placebo 28 days apart</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Infants Group 3: 400U EV71 vaccine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>24 infants received 3 doses of 400U EV71 vaccine 28 days apart</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Infants Group 3: Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>8 infants received 3 doses of placebo 28 days apart</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>100U inactivated Enterovirus Type 71 Vaccine</intervention_name>
    <description>Inactivated Enterovirus Type 71 Vaccine, 100U per 0.5ml per dose. Vaccine will be administered as a single 0.5 mL intramuscular injection in the deltoid muscle of the arm</description>
    <arm_group_label>Infants Group 1: 100U EV71 vaccine</arm_group_label>
    <other_name>EV71 vaccine</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>200U inactivated Enterovirus Type 71 Vaccine</intervention_name>
    <description>Inactivated Enterovirus Type 71 Vaccine, 200U per 0.5ml per dose. Vaccine will be administered as a single 0.5 mL intramuscular injection in the deltoid muscle of the arm</description>
    <arm_group_label>Children Group 1: 200U EV71 vaccine</arm_group_label>
    <arm_group_label>Infants Group 2: 200U EV71 vaccine</arm_group_label>
    <other_name>EV71 vaccine</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>400U inactivated Enterovirus Type 71 Vaccine</intervention_name>
    <description>Inactivated Enterovirus Type 71 Vaccine, 400U per 0.5ml per dose. Vaccine will be administered as a single 0.5 mL intramuscular injection in the deltoid muscle of the arm</description>
    <arm_group_label>Children Group 2: 400U EV71 vaccine</arm_group_label>
    <arm_group_label>Infants Group 3: 400U EV71 vaccine</arm_group_label>
    <other_name>EV71 vaccine</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo, all components of the trial vacccine except for the Enterovirus Type 71 virus antigen, 0.5ml per dose. Placebo will be administered as a single 0.5 mL intramuscular injection in the deltoid muscle of the arm</description>
    <arm_group_label>Children Group 1: Placebo</arm_group_label>
    <arm_group_label>Children Group 2: Placebo</arm_group_label>
    <arm_group_label>Infants Group 1: Placebo</arm_group_label>
    <arm_group_label>Infants Group 2: Placebo</arm_group_label>
    <arm_group_label>Infants Group 3: Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Healthy males and females, aged from 6 months to 11 years old Health is determined by
             medical history, physical examination, laboratory examination and clinical judgment of
             the investigator

          2. Provided legal identification for the sake of recruitment.

          3. Subjects and/or parent(s)/legal guardian(s) are able to understand and sign informed
             consents.

          4. Birth weight more than 2500 grams

        Exclusion Criteria:

          1. Histroy of Hand-foot-mouth Disease

          2. Subject that has allergic history of vaccine, or allergic to any ingredient of vaccine

          3. Serious adverse reactions to vaccines such as anaphylaxis, hives, respiratory
             difficulty, angioedema, or abdominal pain

          4. Congenital malformations or developmental disorders, genetic defects, or severe
             malnutrition

          5. Epilepsy, seizures or convulsions history, or family history of mental illness

          6. Autoimmune disease or immunodeficiency, or parents, brothers and sisters have
             autoimmune diseases or immunodeficiency

          7. History of asthma, angioedema, diabetes or malignancy

          8. History of thyroidectomy or thyroid disease that required medication within the past
             12 months

          9. Bleeding disorder diagnosed by a doctor (e.g. factor deficiency, coagulopathy, or
             platelet disorder requiring special precautions) or significant bruising or bleeding
             difficulties with IM injections or blood draws

         10. Asplenia, functional asplenia or any condition resulting in the absence or removal the
             spleen

         11. Acute illness or acute exacerbation of chronic disease within the past 7 days

         12. Any history of immunosuppressive medications or cytotoxic medications or inhaled
             corticosteroids within the past six months (with the exception of corticosteroid nasal
             spray for allergic rhinitis or topical corticosteroids for an acute uncomplicated
             dermatitis)

         13. History of any blood products within 3 months

         14. Administration of any live attenuated vaccine within 28 days

         15. Administration of subunit or inactivated vaccines ,e.g., pneumococcal vaccine, or
             allergy treatment within 14 days

         16. Axillary temperature &gt; 37.0 centigrade before vaccination

         17. Abnormal laboratory parameters before vaccination

         18. Any medical, psychiatric, social condition, occupational reason or other
             responsibility that, in the judgment of the investigator, is a contraindication to
             protocol participation or impairs a volunteer's ability to give informed consent
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>6 Months</minimum_age>
    <maximum_age>11 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yan-pin Li, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Guangxi Centers for Disease Control and Prevention</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>GuangXi Center for Diseases Control and Prevention</name>
      <address>
        <city>Nanning</city>
        <state>Guangxi</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>July 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 7, 2011</study_first_submitted>
  <study_first_submitted_qc>January 7, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 10, 2011</study_first_posted>
  <last_update_submitted>July 21, 2011</last_update_submitted>
  <last_update_submitted_qc>July 21, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 25, 2011</last_update_posted>
  <responsible_party>
    <name_title>Wei-Dong Yin</name_title>
    <organization>Sinovac Biotech Co., Ltd</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Mouth Diseases</mesh_term>
    <mesh_term>Enterovirus Infections</mesh_term>
    <mesh_term>Foot-and-Mouth Disease</mesh_term>
    <mesh_term>Hand, Foot and Mouth Disease</mesh_term>
    <mesh_term>Virus Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

